Cardiff Oncology (CRDF) Operating Leases (2019 - 2025)

Cardiff Oncology has reported Operating Leases for 7 years, with the latest figure at $102000.0 in Q4 2025.

• Quarterly Operating Leases fell 87.45% year-over-year to $102000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $102000.0 (down 87.45% YoY) and the FY2025 annual result came in at $102000.0, down 87.45% from the prior year.
• Operating Leases declined to $102000.0 in Q4 2025 per CRDF's latest filing, from $284000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $3.3 million in Q3 2021 and troughed at $102000.0 in Q4 2025.
• A 5-year average of $1.5 million and a median of $1.4 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2021 and 2025: Operating Leases jumped 34555.56% in 2021, then plunged 87.45% in 2025.
• Over 5 years, Operating Leases stood at $3.1 million in 2021, then dropped by 12.95% to $2.7 million in 2022, then slumped by 46.3% to $1.5 million in 2023, then tumbled by 44.24% to $813000.0 in 2024, then slumped by 87.45% to $102000.0 in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $102000.0, $284000.0, and $464000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.